Background {#S0001}
==========

Endolymphatic sac tumors (ELSTs) are rare, large primary neoplasms of the temporal bone that are benign but locally invasive \[[@B1]\]. They arise from the endolymphatic sac or ducts of the inner ear, progressing slowly to erode adjacent structures including into the cerebellopontine angle (CPA). Common symptoms -- secondary to involvement of the structures within the CPA -- include progressive hearing loss, tinnitus, vertigo, headache, imbalance or ataxia and nausea/vomiting \[[@B2],[@B3]\]. Hydrocephalus and its sequelae, from compression of the fourth ventricle, may be seen \[[@B4]\]. ELSTs have a female preponderance and are diagnosed in the first through eighth decades of life with a median age of presentation in the fourth decade \[[@B4],[@B5]\]. These neoplasms are often associated with von Hippel-Lindau (vHL) syndrome but may also occur sporadically, with some cases due to somatic mutation of the *VHL* tumor suppressor gene \[[@B2],[@B6]--[@B12]\]. Treatment is early resection to avoid permanent neurologic deficits, and complete resection is potentially curative \[[@B13],[@B14]\]. Adjuvant radiotherapy may slow or stop progression of disease in patients undergoing subtotal resection, though regrowth has been seen in about half of patients \[[@B13],[@B15]\]. There is no standard or established chemotherapeutic regimen, which is especially problematic for patients in whom resection is subtotal or not possible due to structural limitations or vascular compromise. However, a posited role of antiangiogenic agents such as sunitinib and bevacizumab in the management of vHL may provide alternative treatments for ELSTs \[[@B1],[@B16],[@B17]\]. For patients in whom these agents are ineffective or not tolerated, novel agents such as pazopanib -- a multi-kinase inhibitor and angiogenic -- may provide new avenues for treatment.

Case report {#S0002}
===========

Our patient originally presented in 1997 at 20 years of age with several months of blurred vision and migraines. He was evaluated at an outside hospital with limited records available for review. Imaging at that time reportedly revealed a CPA mass, and he underwent a partial resection of this lesion. Initial tissue diagnosis was meningioma versus paraganglioma. In 2008, a repeat resection was attempted but was unsuccessful due to the hemorrhagic nature of the lesion. Tissue diagnosis at the outside institution was WHO grade I meningioma, meningothelial type.

The patient was overall stable until December 2012, when symptoms accelerated and he developed generalized weakness affecting the legs predominantly. From February to April 2013, the patient received radiation of the neck and brain at a total dose of 54 Gy. However, while receiving radiation treatment, the patient's weakness progressed to needing a cane for ambulation.

In July 2013, the patient established care with the neuro-oncology team at our institution for further management of his left skull base tumor. By then, his weakness had progressed, particularly in the left leg. Initial imaging is seen in [Figure 1](#F1){ref-type="fig"}.

![Post-contrast axial T1 image from July 2013 demonstrating left-sided tumor extending into the cerebellum, middle fossa and upper neck.](cns-09-50-g1){#F1}

At the time of initial consultation, the patient had received no chemotherapy. With a working diagnosis of nonresectable meningioma or paraganglioma, treatment was initiated with temozolomide with cycle 1 dosing of 50 mg/m^2^ for 5 days, followed by monthly cycles of 200 mg/m^2^ for 5 days each. This decision was guided by evidence of clinical response in several studies and case series \[[@B18]--[@B20]\]. Between July 2013 and August 2014, our patient received 14 cycles of temozolomide with minor/partial radiographic response and symptom stabilization by November 2013. He would later receive eight additional cycles of temozolomide at 200 mg/m^2^, for a total of 22 cycles, from October 2016 to May 2017, after imaging in February 2016 revealed increased tumor burden.

Regular follow-up appointments, off treatment, occurred from March 2014 through early 2016. Symptoms were stable with only intermittent headaches reported. Interval MRI scans showed continued slow growth of his tumor, and the decision to begin treatment with bevacizumab was made. Twelve biweekly infusions of bevacizumab at 10 mg/kg occurred between June and December 2017.

In July 2017, the pathology department at our institution obtained slides from the patient's 2008 biopsy. Review of histology in our laboratory determined his tumor to be a papillary epithelial neoplasm most consistent with an ELST. There was no apparent necrosis, and the tissue was suboptimally preserved to recognize mitotic figures. No brain parenchyma was noted in the specimen. Our patient was referred to a geneticist for screening for vHL, and genetic testing did not demonstrate a germline *VHL* gene mutation. CT scans of the chest, abdomen and pelvis were negative for other neoplasms or vascular anomalies.

Unfortunately, in January 2018, our patient was hospitalized for epidural abscess and influenza. He underwent left mastoidectomy for biopsy and debridement, left ear canal tumor biopsy and redo left craniectomy with resection and evacuation of abscess. The ear canal tumor biopsy demonstrated involvement by the ELST. A question posed during his January hospitalization was whether bevacizumab may have contributed, likely indirectly, to the formation of his abscess by impairing wound healing, possibly through decreased vascularization. Additionally, his tumor continued to enlarge while on this treatment as seen on follow-up MRI in April 2018, which revealed increasing tumor burden particularly of the intracranial component pressing on the left brachium pontis and brainstem.

In June 2018, partial embolization of arterial feeders to the tumor was performed with a reduction of more than 70% of the tumoral blush, though follow-up MRI in October 2018 was stable compared with July and April 2018, without reduction in tumor size.

Tissue from the January 2018 biopsy was sent for genetic analysis by Foundation One (Foundation Medicine, MA, USA), which demonstrated a somatic *VHL* L89R missense mutation, *TERT* promoter mutation −124C\>T, stable microsatellite status, and low tumor mutation burden. There are currently no US FDA-approved targeted therapies for ELSTs; however, a Phase II trial of pazopanib by Jonasch *et al.* in 2018 demonstrated decreased tumor burden in patients with vHL-associated neoplasms. Given the association between vHL and ELST, as well as the suspected pathophysiology of these neoplasms, clinical response noted in these trials intimated a potential therapeutic response to pazopanib for our patient.

After discussing the risks, benefits and alternatives of this off-label application, treatment with pazopanib was initiated in November 2018 at a dose of 800 mg daily. This was well tolerated after a dose reduction to 400 mg daily in January 2019 given skin lightening and fatigue. Follow-up imaging demonstrated -- as soon as December 2018 -- significant reduction in tumor burden on this therapy. MRI brain comparing MRI in April 2019 to pretreatment imaging is seen in [Figure 2](#F2){ref-type="fig"}.

![Radiographic response to pazopanib.\
 Left is a post-contrast axial T1 MRI from October 2018 prior to initiation of pazopanib. Right is a post-contrast axial T1 MRI from April 2019 following initiation of pazopanib.](cns-09-50-g2){#F2}

Discussion {#S0003}
==========

A multisystem familial cancer syndrome, vHL is characterized by CNS hemangioblastomas, retinal hemangiomas, renal cell cancer of the clear cell type, renal or pancreatic cysts, pancreatic neuroendocrine tumors, pheochromocytomas and papillary cyst adenomas of the epididymis or broad uterine ligament; ELSTs have been reported in 9--16% of cases of vHL \[[@B2],[@B6]--[@B8]\]. Conversely, in a series of 49 patients with diagnosed ESLTs, 24% had vHL \[[@B9]\]. Some cases of sporadic ELST have been associated with somatic mutation of the *VHL* tumor suppressor gene \[[@B10]--[@B12]\]. Treatment of ELST is primarily surgical, with complete resection being potentially curative \[[@B4],[@B13]\]. There is an emphasis on early intervention as neurologic deficits may be permanent \[[@B13],[@B14]\]. Adjuvant radiotherapy is not standard of care, though it has been shown to slow or stop progression of disease in half of patients undergoing subtotal resection \[[@B13],[@B15]\]. The role of chemotherapeutic agents in the treatment of ELST is not clear, though patients in whom a subtotal resection is performed would benefit from nonsurgical interventions. To date, there have been no clinical trials of chemotherapeutic agents for ELST. Rather, the medications used in prior case reports are treatments studied in vHL alone, as an extension of the strong association between ELST and vHL. Given the highly vascular nature of tumors that form in vHL, including ELST, a putative mechanism for antiangiogenic agents such as sunitinib and bevacizumab in the management of this syndrome has been proposed and may provide alternative treatments for ELSTs \[[@B1],[@B16],[@B17]\].

Bevacizumab is a humanized monoclonal antibody against VEGF-A, which is believed to be the primary driver of tumor angiogenesis \[[@B21],[@B22]\]. This medication is a potent antiangiogenic used as single agent or in conjunction with other chemotherapeutics in the treatment of metastatic colorectal cancer, non-small-cell lung cancer, renal cell carcinoma, advanced ovarian cancer and recurrent glioblastoma \[[@B21]\]. Although VEGF-A is implicated in the formation of blood vessels, angiogenesis is complex and consists of signaling pathways that incorporate PGF, FGFs, PDGFs, angiopoietins, various cytokines, PDGF-BB, ephrin-B2 and NOTCH \[[@B23]\]. Therefore, it has been proposed that agents inhibiting more of these targets, or affecting downstream signaling cascades, would provide more robust antitumor effects. One such agent is pazopanib.

Pazopanib (Votrient; GlaxoSmithKline, London, UK) is a kinase inhibitor that targets several tyrosine kinases including VEGF receptors 1, 2 and 3, as well as PDGF alpha, beta and KIT \[[@B24],[@B25]\]. This agent was approved by the US FDA in 2009 for the treatment of advanced renal cell carcinoma, and in 2012 extended its indications to include advanced soft tissue sarcoma in patients who had previously received other chemotherapy \[[@B26]\]. An illustration of the sites of action of pazopanib is seen in [Figure 3](#F3){ref-type="fig"}.

![Sites of action of notable antiangiogenic agents.](cns-09-50-g3){#F3}

Trials of pazopanib as single agent therapy for various neoplasms -- within and outside the CNS -- have demonstrated mixed response. In a Phase II trial by Iwamoto *et al.* in 2010, the safety and efficacy of pazopanib for recurrent glioblastomas was tested. Their primary end point for efficacy was progression-free survival at 6 months (PFS6). In these patients, despite tolerating the medication relatively well, the PFS6 rate was poor at 3%; this was significantly lower than trials of bevacizumab that demonstrated rates of 29--43% in a similar patient population \[[@B27],[@B28]\]. Although the efficacy outcome was low, there was evidence that pazopanib did have *in situ* biological activity in this patient cohort \[[@B29]\]. Though not fully understood, the mechanism of tumor response may be due to normalization of abnormal tumor blood vessels rather than direct antiangiogenic or antitumor properties.

A Phase II trial of pazopanib as second-line therapy in patients with metastatic or locally unresectable renal clear cell carcinoma who had previously received single agent treatment with bevacizumab or sunitinib was conducted by Hainsworth *et al.* in 2013. In this study, 15 of 55 (27%) patients demonstrated objective response to pazopanib and another 27 (49%) had stable disease for a disease control rate of 76%. Of the 45 patients in whom disease progressed while on first line treatment, 10 (22%) demonstrated response with a disease control rate of 75% \[[@B30]\]. More recently, Jonasch *et al.* demonstrated in a Phase II, single center trial that patients with diagnosed vHL may see response to tumors of multiple organs when started on pazopanib therapy \[[@B31]\]. Of the 31 patients treated with pazopanib, 13 (42%) demonstrated objective response with the most pronounced effect in pancreatic lesions (9 of 17, 53%) and renal cell carcinomas (31 of 59, 52%); only 2 of 49 (4%) CNS hemangioblastomas demonstrated objective response \[[@B31]\]. These trials illustrate the treatment potential of pazopanib in patients with various tumor types, including those often associated with vHL.

Despite some promise seen with antiangiogenic therapies in patients with unresectable or partially resected ELSTs, treatment options remain limited. In our patient, diagnosed with his CPA neoplasm at age 20, the high vascularity of his lesion limited resection. Subsequent treatment with radiation therapy did not hinder growth and treatment response with temozolomide was transient. Bevacizumab likewise demonstrated only temporary disease control, and this therapy may have contributed indirectly to the development of an epidural abscess. Genetic testing did not identify a novel therapeutic target but was notable for a *VHL* L89R mutation. The clinical significance of the *VHL* L89R mutation is not characterized, and the effect on pVHL protein function is unknown. In a series of six patients with the *VHL* L89R mutation in the COSMIC database, five were associated with clear cell type renal cell carcinoma and one with CNS hemangioblastoma \[[@B32],[@B33]\]; neither of these tumor types has been identified in our patient. With no specific genetic target and promising trials, pazopanib was initiated as third line therapy in our patient with significant reduction in tumor burden to date.

The sites of action of pazopanib may in part explain our patient's improved response to this therapy. In particular, disruption of tyrosine kinase signaling cascades rather than scavenging VEGF-A -- the mechanism of bevacizumab -- may provide longer-term reduction in tumor burden. Additionally, there may be decreased development of resistance to this therapy. The authors acknowledge that this is a single case report and that no clinical trial has yet been performed to assess the response of ELSTs to pazopanib therapy. Given the rare nature of this condition, a prospective clinical trial is likely not feasible. There remains a dearth of available systemic therapies for vHL syndrome, but as more trials are conducted, the frontiers of treatment options for vHL that may extend to ESLT will continue to shift.

###### Summary points

-   Nonsurgical treatment options for patients with endolymphatic sac tumors remain limited.

-   However, there is demonstrated potential for antiangiogenic agents in our patient and previous case series.

-   In our patient, treatment with pazopanib, a tyrosine kinase inhibitor with antiangiogenic properties, has resulted in decreased lesional burden that may provide evidence for a novel therapy for endolymphatic sac tumors.
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